HealthEquity Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

HealthEquity (HQY) is scheduled to report Q2 earnings on September 2, with analysts forecasting EPS of $0.92 on $320.69 million in revenue, an increase from the prior year. This follows a strong Q1 where HQY surpassed consensus with $0.97 EPS and $330.8 million in revenue. The stock closed up 1.2% on Friday, bolstered by positive analyst sentiment, including an Outperform rating with a $125 price target from Barrington Research and a Strong Buy rating with a raised $120 target from Raymond James.

Analysis

HealthEquity, Inc. (HQY) is approaching its second-quarter earnings release on September 2 with strong positive sentiment from analysts and a recent history of outperformance. The consensus estimate projects year-over-year growth, with expected EPS of $0.92 (up from $0.86) and revenue of $320.69 million (up from $299.93 million). This follows a robust first quarter where the company surpassed expectations, delivering EPS of $0.97 against a forecast of $0.88 and revenue of $330.8 million versus an estimated $321.17 million. This pattern of beating estimates has likely contributed to the bullish stance from highly-rated analysts, including an Outperform rating with a $125 price target from Barrington Research and a Strong Buy rating with an increased price target of $120 from Raymond James. These price targets suggest a significant potential upside from the stock's recent closing price of $89.33, which itself reflected a 1.2% gain, indicating positive market momentum heading into the earnings announcement.

Key Decisions for Investors

• Given the consistent earnings beats, positive analyst ratings, and significant upside implied by price targets, investors could consider establishing or increasing a long position in HQY ahead of the September 2nd earnings report.
• Monitor the upcoming Q2 earnings release closely, as the stock's recent positive momentum and high expectations create a risk of a sharp pullback if the company fails to meet or exceed the consensus EPS of $0.92 and revenue of $320.69 million.
• Investors should pay close attention to the company's forward-looking guidance in the earnings call, as any weakness in the outlook could overshadow a strong Q2 performance and impact the stock's trajectory.